Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 4/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13366391 | 0.97 | — | — | |
| SCHEMBL276778 | 0.97 | — | — | |
| SCHEMBL5049546 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL10336374 | 0.95 | — | — | |
| SCHEMBL3392036 | 0.83 | ALDH1A1 (0.38) | CA2ECE1ALDH1A1TDP1TSHR | |
| SCHEMBL19619339 | 0.78 | CA1 (0.37) | CA1CA2CA7CA14ECE1 | |
| SCHEMBL11413659 | 0.78 | ECE1 (0.35) | CA2ECE1ALDH1A1TDP1ALOX15 | |
| Acetamide SCHEMBL4103797 | 0.78 | LMNA (0.47) | CA2ECE1ALDH1A1TDP1ALOX15 | |
| SCHEMBL25078569 | 0.77 | — | — | |
| SCHEMBL276380 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057798-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2025-02-20 | — | — | US | disclosed |
| US-12090131-B2 | Therapeutic use of compounds | UCL BUSINESS LTD (GB) | 2024-09-17 | — | — | US | disclosed |
| US-20230146709-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2023-05-11 | — | — | US | disclosed |
| US-11491127-B2 | Therapeutic use of compounds | UCL BUSINESS PLC (GB) | 2022-11-08 | — | — | US | disclosed |
| US-11419839-B2 | Therapeutic use of compounds | UCL BUSINESS LTD (GB) | 2022-08-23 | — | — | US | disclosed |
| EP-2737901-B1 | Therapeutic Use of Compounds | UCL BUSINESS LTD (GB) | 2021-03-03 | — | — | EP | disclosed |
| US-20200268699-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-08-27 | — | — | US | disclosed |
| US-20200197344-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-06-25 | — | — | US | disclosed |
| EP-3636259-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-04-15 | — | — | EP | disclosed |
| US-10548866-B2 | Therapeutic use of compounds | UCL BUSINESS LTD (GB) | 2020-02-04 | — | — | US | disclosed |
| EP-2642990-B1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS PLC (GB) | 2019-09-18 | — | — | EP | disclosed |
| EP-2737901-A1 | Therapeutic Use of Compounds | UCL Business PLC (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20130303616-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS PLC (GB) | 2013-11-14 | — | — | US | disclosed |
| EP-2642990-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL Business Plc. (GB) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069790-A1 | THERAPEUTIC USE OF COMPOUNDS | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146709-A1 | THERAPEUTIC USE OF COMPOUNDS | SGMS1, CHRM1, CYP11B1 | CA1 1504/4885CA2 2395/4885CA7 862/4885 |
| US-20200268699-A1 | THERAPEUTIC USE OF COMPOUNDS | DEGS1, CYP11B1, SGMS1 | CA1 1687/4885CA2 2879/4885CA7 1072/4885 |
| US-20130303616-A1 | THERAPEUTIC USE OF COMPOUNDS | BACE1, CPT1A, BCL6 | CA1 1559/4885CA2 3274/4885CA7 3452/4885 |
| US-10548866-B2 | Therapeutic use of compounds | BACE1, BCL6, BCL6B | CA1 1581/4885CA2 2995/4885CA7 3131/4885 |
| US-20250057798-A1 | THERAPEUTIC USE OF COMPOUNDS | CYP11B1, SGMS1, PTGER1 | CA1 1286/4885CA2 2311/4885CA7 965/4885 |
| US-12090131-B2 | Therapeutic use of compounds | SGMS1, CHRM1, CYP11B1 | CA1 1504/4885CA2 2395/4885CA7 862/4885 |
| US-11419839-B2 | Therapeutic use of compounds | SGMS1, CHRM1, CYP11B1 | CA1 1504/4885CA2 2395/4885CA7 862/4885 |
| US-11491127-B2 | Therapeutic use of compounds | SGMS1, CHRM1, CYP11B1 | CA1 1504/4885CA2 2395/4885CA7 862/4885 |
| US-20200197344-A1 | THERAPEUTIC USE OF COMPOUNDS | SGMS1, CHRM1, CYP11B1 | CA1 1504/4885CA2 2395/4885CA7 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.